NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Reference is made to the stock notice from SoftOx Solutions AS (the "Company") on 11 September 2025 regarding the board resolution to exercise on the financing facility with Long State Investments Limited.
The private placement has been successfully completed at a subscription price of NOK 0,10, with Long State subscribing for 60 000 000 shares in the Company. The subscription price corresponds to the Company’s minimum subscription price. In accordance with the financing facility, Long State received a placement commission on market terms.
Following the private placements, the new share capital of the Company will be NOK 46 308 339,88 divided into 2 315 416 994 shares, each with a par value of NOK 0,02.
For more information on the financing facility, please see the Company's stock exchange release dated 14 August 2025.
For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com
About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.